Breast Cancer Clinical Trial

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Summary

This study is a retrospective, multi-site, patient-level medical chart review of US adult patients with locally advanced or metastatic breast cancer (ABC) who initiated talazoparib on or after October 16, 2018 and were managed by participating providers from Cardinal Health's Oncology Provider Extended Network (OPEN).

This study will describe patient characteristics, treatment patterns, and clinical outcomes of talazoparib-treated patients in real-world practice setting in US.

The primary population for this study includes:

-HER2-negative ABC patients with germline BRCA1/2 (gBRCA1/2) mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosed with HER2-negative ABC
gBRCA1/2 mutation(s)

Treatment with talazoparib monotherapy initiated on or after October 16, 2018

-≥18 years of age at initiation of talazoparib

A minimum of 6 months follow-up time after initiation of talazoparib unless the patient died within this follow-up period

Exclusion Criteria:

Participation in any BC clinical trial after initiation of talazoparib
Treatment with a PARP inhibitor as neoadjuvant/adjuvant therapy
gBRCA1/2 or HER2 status unknown
Diagnosis of any other malignancy, except carcinoma in situ or nonmelanoma skin cancer, within the 5 years prior to data collection

Study is for people with:

Breast Cancer

Estimated Enrollment:

84

Study ID:

NCT04987931

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Pfizer Inc
New York New York, 10017, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

84

Study ID:

NCT04987931

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.